A Randomized, Controlled Trial Evaluating Efficacy of Perioperative Organ Protection as Well as Safety of Ulinastatin Use in Pediatric Patients Undergoing Open Heart Surgery Through CPB to Treat Complex Congenital Heart Diseases
Phase of Trial: Phase IV
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Ulinastatin (Primary)
- Indications Congenital heart defects
- Focus Therapeutic Use
- Sponsors Techpool Bio-Pharma
- 16 Jan 2018 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018.
- 16 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.
- 13 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Mar 2018.